Neville Rodie & Shaw Inc. Lowers Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Neville Rodie & Shaw Inc. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 122,753 shares of the company's stock after selling 3,634 shares during the period. Zoetis accounts for approximately 1.6% of Neville Rodie & Shaw Inc.'s investment portfolio, making the stock its 17th biggest position. Neville Rodie & Shaw Inc.'s holdings in Zoetis were worth $20,212,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after buying an additional 140 shares during the last quarter. Rakuten Securities Inc. raised its position in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the period. Navigoe LLC purchased a new stake in Zoetis in the fourth quarter valued at $30,000. Murphy & Mullick Capital Management Corp purchased a new stake in Zoetis in the fourth quarter valued at $44,000. Finally, Asset Planning Inc purchased a new stake in Zoetis in the fourth quarter valued at $58,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of research analyst reports. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Piper Sandler boosted their price objective on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Finally, Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $212.75.

Zoetis Stock Down 0.3%

Shares of ZTS traded down $0.44 during mid-day trading on Monday, reaching $168.19. The company's stock had a trading volume of 941,392 shares, compared to its average volume of 2,520,986. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The stock has a market cap of $74.88 billion, a PE ratio of 30.75, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company's 50 day moving average is $156.80 and its 200 day moving average is $164.43.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter in the prior year, the business posted $1.38 EPS. The business's revenue for the quarter was up 1.4% on a year-over-year basis. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.19%. Zoetis's dividend payout ratio is presently 35.91%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their position. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by company insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.